Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AVTE NYSE:CYBN NASDAQ:NLTX NASDAQ:PYR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAVTEAerovate Therapeutics$9.51+7.9%$8.54$56.35▼$105.00$275.65M0.9512,385 shs171,880 shsCYBNCybin$8.32-1.7%$7.83$4.81▼$13.88$194.78M0.69290,283 shs436,714 shsNLTXNeoleukin Therapeutics$22.60+0.3%$19.01$2.03▼$14.36$212.40M1.1150,104 shs135,052 shsPYRPyroGenesis Canada$0.38$0.38$0.26▼$1.30$67.96M0.747,701 shs29,889 shsInvesting Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAVTEAerovate Therapeutics+7.95%-9.60%+14.72%-90.12%-85.62%CYBNCybin-1.65%+8.90%+5.32%+13.20%+2,154.74%NLTXNeoleukin Therapeutics+0.27%+6.30%+22.69%+96.69%-49.03%PYRPyroGenesis Canada0.00%0.00%0.00%0.00%0.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAVTEAerovate TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/ACYBNCybin3.0583 of 5 stars3.60.00.00.03.70.81.3NLTXNeoleukin TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/APYRPyroGenesis CanadaN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAVTEAerovate Therapeutics 0.00N/AN/AN/ACYBNCybin 3.25Buy$85.00921.63% UpsideNLTXNeoleukin Therapeutics 0.00N/AN/AN/APYRPyroGenesis Canada 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest PYR, AVTE, NLTX, and CYBN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/8/2025CYBNCybinCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$73.00 ➝ $70.005/13/2025CYBNCybinCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy(Data available from 7/19/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAVTEAerovate TherapeuticsN/AN/AN/AN/A$3.96 per shareN/ACYBNCybinN/AN/AN/AN/A$10.83 per shareN/ANLTXNeoleukin TherapeuticsN/AN/AN/AN/A$11.08 per shareN/APYRPyroGenesis Canada$14.63M4.65N/AN/A$0.07 per share5.43Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAVTEAerovate Therapeutics-$75.52M-$1.70N/AN/AN/AN/A-90.19%-77.47%8/11/2025 (Estimated)CYBNCybin-$57.88M-$3.88N/AN/AN/AN/A-37.58%-36.59%N/ANLTXNeoleukin Therapeutics-$57.56M-$3.11N/A∞N/AN/A-37.22%-30.91%N/APYRPyroGenesis Canada-$24.74M-$0.11N/A∞N/A-233.18%-194.66%-68.91%N/ALatest PYR, AVTE, NLTX, and CYBN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/11/2025Q2 2025AVTEAerovate Therapeutics-$0.25N/AN/AN/AN/AN/A4/25/2025Q4 2024AVTEAerovate Therapeutics-$10.50-$3.15+$7.35-$0.09N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAVTEAerovate TherapeuticsN/AN/AN/AN/AN/ACYBNCybinN/AN/AN/AN/AN/ANLTXNeoleukin TherapeuticsN/AN/AN/AN/AN/APYRPyroGenesis CanadaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAVTEAerovate TherapeuticsN/A8.788.78CYBNCybinN/A24.2424.24NLTXNeoleukin TherapeuticsN/A15.3315.33PYRPyroGenesis Canada0.260.860.78Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAVTEAerovate TherapeuticsN/ACYBNCybin17.94%NLTXNeoleukin Therapeutics52.37%PYRPyroGenesis Canada0.41%Insider OwnershipCompanyInsider OwnershipAVTEAerovate Therapeutics24.90%CYBNCybin15.00%NLTXNeoleukin Therapeutics1.58%PYRPyroGenesis Canada47.68%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAVTEAerovate Therapeutics2028.99 million21.69 millionOptionableCYBNCybin5023.02 million17.96 millionNot OptionableNLTXNeoleukin Therapeutics909.40 million9.25 millionNo DataPYRPyroGenesis Canada2,020178.88 million93.59 millionNot OptionablePYR, AVTE, NLTX, and CYBN HeadlinesRecent News About These CompaniesPyroGenesis announces completion of coke-oven gas valorization and H2 production project for Tata SteelJuly 15, 2025 | hydrocarbonprocessing.comHPyroGenesis Improves Fumed Silica Quality, Purity, and Consistency Across Multiple Production Cycles - MorningstarJuly 9, 2025 | morningstar.comMPyroGenesis Inc.: PyroGenesis Reports Voting Results from 2025 Annual Meeting of ShareholdersJune 28, 2025 | finanznachrichten.dePyroGenesis: Top 10 Undervalued Industrial Products Industry Stocks (PYR)June 14, 2025 | theglobeandmail.comPyroGenesis achieves approved supplier status with Boeing for titanium AM powdersMay 30, 2025 | voxelmatters.comVBuzz on the Bullboards: Bombardier vs Boeing, MediPharm “under attack”May 29, 2025 | msn.comEarnings call transcript: PyroGenesis Q4 2024 sees strong revenue growthApril 3, 2025 | uk.investing.comPyroGenesis Full Year 2024 Earnings: CA$0.04 loss per share (vs CA$0.16 loss in FY 2023)April 3, 2025 | finance.yahoo.comEquity Markets Mixed as Canada Trade Tensions SimmerMarch 11, 2025 | msn.comPyroGenesis successfully operates fumed silica reactor pilot plantFebruary 27, 2025 | canadianmanufacturing.comCBuzz on the Bullboards: No tariffs? No problem!February 6, 2025 | msn.comPyroGenesis Inc.: PyroGenesis Provides Update on Impact of Potential U.S. TariffsFebruary 6, 2025 | finanznachrichten.dePyroGenesis receives $1.85M under Drosrite contractJanuary 21, 2025 | canadianmanufacturing.comCFederal government invests in Cdn. technologies to support clean fuelsJanuary 8, 2025 | canadianmanufacturing.comCGovernment invests $11M in Canadian technologies to advance clean fuelsJanuary 8, 2025 | plant.caPPyroGenesis Canada Tackles PFAS with Plasma TechnologyDecember 4, 2024 | markets.businessinsider.comBuzz on the Bullboards: Stocks to watch in volatile times.November 28, 2024 | msn.comPyroGenesis Canada Optimistic About U.S. Policy ChangesNovember 20, 2024 | markets.businessinsider.comPyroGenesis Partners with Global Steel GiantNovember 20, 2024 | markets.businessinsider.comStocks in play: PyroGenesis Inc.November 12, 2024 | ca.finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimePYR, AVTE, NLTX, and CYBN Company DescriptionsAerovate Therapeutics NASDAQ:AVTE$9.51 +0.70 (+7.95%) As of 07/17/2025Aerovate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. It focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial. The company was incorporated in 2018 and is headquartered in Waltham, Massachusetts.Cybin NYSE:CYBN$8.32 -0.14 (-1.65%) Closing price 07/18/2025 04:00 PM EasternExtended Trading$8.36 +0.04 (+0.49%) As of 07/18/2025 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Cybin Inc., a clinical-stage biopharmaceutical company, focuses on developing psychedelic-based therapeutics for patients with mental health conditions. The company's development pipeline includes CYB003, a deuterated psilocybin analog, which is in phase 1/2a clinical trial to treat major depressive disorder (MDD), as well as in preclinical trials for alcohol use disorder; CYB004, a deuterated dimethyltryptamine (DMT), which completed phase 2 clinical trial for treating generalized anxiety disorders; SPL028 injectable deuterated DMT completed phase 1 clinical intramuscular and intravenous trial; SPL026 completed phase 1, 1b, and 1/2a for MDD; and CYB005, a phenethylamine derivative, which in preclinical stage to treat neuroinflammation, as well as has a research pipeline of investigational psychedelic-based compounds. The company has research and collaboration agreement with TMS Neurohealth Centers Inc. for development of psychedelic compound-based therapeutics; Kernel for use of Kernel flow technology to measure neural activity; and Greenbook TMS to establish mental health centers. The company is headquartered in Toronto, Canada.Neoleukin Therapeutics NASDAQ:NLTX$22.60 +0.06 (+0.27%) As of 07/17/2025Neoleukin Therapeutics, Inc., a biopharmaceutical company, develops immunotherapies for cancer, inflammation, and autoimmunity disorders using protein design technology. The company's lead product candidate is NL-201, a de novo protein designed to mimic the therapeutic activity of the cytokines interleukin (IL)-2/IL-15 for the treatment of various types of cancer, including renal cell carcinoma and melanoma. The company was formerly known as Aquinox Pharmaceuticals, Inc. and changed its name to Neoleukin Therapeutics, Inc. in August 2019. Neoleukin Therapeutics, Inc. was founded in 2003 and is headquartered in Seattle, Washington.PyroGenesis Canada NASDAQ:PYRPyroGenesis Canada Inc. designs, develops, manufactures, and commercializes plasma processes and solutions worldwide. It offers DROSRITE, a process for enhancing metal recovery from dross without any hazardous by-products; plasma atomization process that allows produce and sell high purity spherical metal powders; PUREVAP, a process to produce high purity metallurgical and solar grade silicon from quartz; and PUREVAP NSiR, which is designed to transform silicon into spherical silicon nano powders and nanowires for use in lithium-ion batteries. The company also provides plasma torches and plasma torch systems used toreplace fossil fuel burners in industrial iron ore pelletization process; plasma arc waste destruction systems for waste destruction onboard ships; steam plasma arc refrigerant cracking systems for the destruction of certain refrigerants, including chlorofluorocarbons, hydrofluorocarbons, and hydrochlorofluorocarbons; plasma arc chemical warfare agent destruction systems, which are mobile platforms for the onsite destruction of chemical warfare agents; plasma resource recovery systems for land-based waste destruction and waste-to-energy applications; plasma torches for waste gasification and combustion; and plasma arc gasification and vitrification. In addition, it offers engineering and manufacturing expertise, and contract research, as well as turnkey process equipment packages to the defense, metallurgical, mining, additive manufacturing (including 3D printing), oil and gas, and environmental industries. Further, the company provides installation, commissioning, and start-up services. PyroGenesis Canada Inc. is headquartered in Montréal, Canada. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Netflix Q2 2025 Earnings: What Investors Need to Know High-Flying GE Aerospace Drops After Blowout Q2 — What Now? A New $70 Billion AI Investment Could Push Taiwan Semiconductor Why Prologis May Be the Smartest Backdoor Bet on AI Real Estate Snap-On: Snap Up This Strong Signal While It’s Still Cheap Why Abbott Laboratories Is a Q2 2025 Buy: Growth & Yield Why Pure Storage Is a Core Investment for the AI Era How Goldman Sachs Earnings Help You Strategize Your Portfolio Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
